(Q44499254)

3 December 2017

title

Significant improvement in frontal lobe associated neuropsychological functions after withdrawal of topiramate in epilepsy patients (English)

1 reference

3 December 2017

1 reference

Edgar Kockelmann

1

1 reference

3 December 2017

Christian E Elger

series ordinal

2

1 reference

3 December 2017

Christoph Helmstaedter

series ordinal

3

1 reference

3 December 2017

publication date

1 May 2003

1 reference

3 December 2017

1 reference

3 December 2017

volume

54

1 reference

3 December 2017

issue

2-3

1 reference

3 December 2017

page(s)

171-178

1 reference

A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures.

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900078-0

7 January 2021

Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900078-0

7 January 2021

Effect of topiramate on attention

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900078-0

7 January 2021

Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900078-0

7 January 2021

Empirical techniques for determining the reliability, magnitude, and pattern of neuropsychological change after epilepsy surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900078-0

7 January 2021

Cognitive impairments due to add-on therapy with topiramate

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900078-0

7 January 2021

Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900078-0

7 January 2021

Abnormal Wada and neuropsychological testing results due to topiramate therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900078-0

7 January 2021

Language Disturbances as Side Effects of Topiramate and Zonisamide Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900078-0

7 January 2021

A pharmacological and clinical review on topiramate, a new antiepileptic drug

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900078-0

7 January 2021

Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900078-0

7 January 2021

Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900078-0

7 January 2021

Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900078-0

7 January 2021

Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900078-0

7 January 2021

Postmarketing experience with topiramate and cognition

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900078-0

7 January 2021

Effects of topiramate on cognitive function

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2803%2900078-0

7 January 2021

10.1016/S0920-1211(03)00078-0

Identifiers

DOI

1 reference

3 December 2017

1 reference